Loteprednol

EyeCare Partners’ Leadership and Clinical Research to be Showcased at American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Thursday, May 4, 2023
Surgery, Health, Science, Research, Optical, Dark, Partner, Eye drop, Ophthalmology, ASCRS, Varenicline, Telecanthus, Patient satisfaction, Ciclosporin, Patient experience, ECP, Presbyopia, Ageing, Randomness, Cataract, Legacy Devers Eye Institute, Wonderful, Manual, Refractive surgery, Endothelium, Ocular hypertension, American Society of Cataract and Refractive Surgery, Somatosensory system, Ketamine, Contact lens, Political moderate, Learning curve, Pilocarpine, DED, Retina, Midazolam, Phacoemulsification, Corneal neovascularization, Loteprednol, Immunosuppression, Physician, Pivotal, Society, Treatment, Rejuvenation, Veterinary medicine, Nursing, Hospital, Telescopic sight, Medical imaging, Pharmaceutical industry, Casino, PRK, Tacrolimus, LASIK, Creatinine, History, Patient

The annual meeting will take place May 5-8, 2023, in San Diego.

Key Points: 
  • The annual meeting will take place May 5-8, 2023, in San Diego.
  • The breadth of topics being presented at ASCRS by ECP physicians emphasizes the company’s culture of innovation and continuous learning.
  • It also underscores the possibility of a career “third pathway” which allows physicians to conduct industry-leading research while also continuing to build a clinical practice.
  • “EyeCare Partners has a strong representation of ophthalmologists presenting research at ASCRS this year, in addition to one of our specialists, Dr. Elizabeth Yeu, serving as the incoming president of ASCRS,” said David Clark, CEO of EyeCare Partners.

Global Dry Eye Syndrome Treatment Market Report 2022 to 2028: Featuring AbbVie, Novartis, Sun Pharmaceuticals Industries and OASIS Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Pharmaceutical, Health, Optical, Plasma protein binding, Approved drug, DE, Therapy, Tears, Duane syndrome, Cornea, FDA, Eyelid, Irritation, Conjunctiva, Growth, Patient, Bausch & Lomb, Loteprednol, Dry eye syndrome, Clinical trial, DED, Eye, Market share, Investment, Mucus, Printed circuit board, Cosmetics, Hospital, Pharmaceutical industry, Dose

The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.

Key Points: 
  • The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.
  • As these development continue to proceed, they aid in the expansion of the dry eye syndrome treatment market.
  • This demonstrates significant drug approval costs that are expected to have an impact on the market for dry eye medications.
  • Additionally, long waiting times also add up to lost money for these manufacturers, and as such hampers the growth of the dry eye syndrome treatment market.

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Retrieved on: 
Monday, May 23, 2022
Medicine, Food, Mycosis, U.S. Securities and Exchange Commission, NCE, Infection, KALA, Visual acuity, MPP, Duane syndrome, IOP, Loteprednol, Private Securities Litigation Reform Act, Steroid, Ophthalmology, Wilmer Cutler Pickering Hale and Dorr, Tissue, Pain, Degenerative disease, Incidence, COVID-19, Marketing, Food and Drug Administration, Chickenpox, Cover My Eyes (Pain and Heaven), GLOBE, Inflammation, Company, Coronavirus, Eye, Herpes simplex, FDA, Conjunctiva, Feed additive, Sclera, Adverse drug reaction, Cornea, Security (finance), Risk, History, Vaccinia, Patient, NASDAQ, LE, Technology, Slit lamp, Glaucoma, Sale, Hart–Scott–Rodino Antitrust Improvements Act, Optic nerve, Health insurance, Pharmaceutical industry, Vaccine, Alcon

ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. This includes EYSUVIS, the first and only U.S. Food and Drug Administration (FDA) approved medicine for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS, a twice-a-day corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery.

Key Points: 
  • Kala plans to focus on developing KPI-012, a novel cell-free secretome therapy that has the potential to address a number of rare and severe ocular diseases.
  • Under the terms of the asset purchase agreement, Kala will receive an upfront payment of $60 million and will be eligible to receive commercial-based sales milestone payments.
  • Piper Sandler acted as the exclusive financial advisor, and Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel to Kala.
  • Kala believes INVELTYS has a favorable profile for the treatment of inflammation and pain following ocular surgery, due to its twice-a-day dosing regimen.

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, U.S. Securities and Exchange Commission, Glaucoma, Medicare, Private Securities Litigation Reform Act, NCE, Chickenpox, Herpes simplex, Adverse drug reaction, IOP, Degenerative disease, NASDAQ, GLOBE, KALA, Medicare Part D, Eye, Patient, Loteprednol, Infection, Pharmacy benefit management, Commercial, Optic nerve, Coronavirus, Conjunctiva, Acquisition, Vaccinia, FDA, Slit lamp, History, Pharmacy, Security (finance), Marketing, Cornea, Visual acuity, LE, Mycosis, Technology, Growth, Duane syndrome, Risk, MPP, Pharmaceutical industry, Health insurance, Humana

ARLINGTON, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the largest Pharmacy Benefit Manager in the United States has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 1, 2022. This adds 28.5 million commercial lives to EYSUVIS coverage, bringing total commercial coverage to 155.3 million lives, or 92% of total commercial lives.

Key Points: 
  • This adds 28.5 million commercial lives to EYSUVIS coverage, bringing total commercial coverage to 155.3 million lives, or 92% of total commercial lives.
  • This adds approximately 7 million Medicare lives to EYSUVIS coverage, bringing total EYSUVIS Medicare coverage to 14.1 million lives, or approximately 30% of all Medicare lives.
  • We are excited to announce this additional payer coverage, which brings our commercial access to 92% of covered lives and doubles our Medicare Part D coverage.
  • Earlier this year, we secured coverage with several large commercial and Medicare Part D plans and, together with these additions, we have now achieved total EYSUVIS coverage for more than 169 million lives.

Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare

Retrieved on: 
Tuesday, March 8, 2022
Duane syndrome, KALA, Security (finance), Medicare, Commercial, COVID-19, Acquisition, Slit lamp, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Herpes simplex, Vaccinia, Technology, FDA, Therapy, Express Scripts, Cornea, Degenerative disease, Visual acuity, History, Conjunctiva, Risk, Optic nerve, Eye, Loteprednol, Marketing, Mycosis, UnitedHealth Group, LE, Chickenpox, Coronavirus, NCE, NASDAQ, Infection, MPP, Patient, Medicare Part D, Cigna, Growth, Adverse drug reaction, IOP, Glaucoma, GLOBE, Pharmaceutical industry

ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that UnitedHealthcare, one of the largest commercial health care plans in the United States, covering approximately 13 million lives, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022. EYSUVIS now has coverage for approximately 118 million lives, or 70% of all commercial lives.

Key Points: 
  • EYSUVIS now has coverage for approximately 118 million lives, or 70% of all commercial lives.
  • Also today, Kala announced that Cigna Medicare has added EYSUVIS as a preferred brand effective February 2022, adding an additional 1.9 million Medicare lives.
  • EYSUVIS now has Medicare preferred coverage for select plans with Express Scripts, Prime Therapeutics and Cigna.
  • Total EYSUVIS Medicare coverage is now approximately 7.1 million lives, or 15% of all Medicare lives.

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021

Retrieved on: 
Monday, November 1, 2021
Automotive, Health, Other Automotive, Pharmaceutical, Optical, Biotechnology, Duane syndrome, MD, Research, Compliance, AMD, Knowledge, Keratoconus, Inflammation, Intraocular pressure, MBA, Security (finance), U.S. Securities and Exchange Commission, Patient, NASDAQ, Comparison, FDA, Private Securities Litigation Reform Act, Ocular hypertension, Eye, Axitinib, Allergy, Allergic conjunctivitis, Company, MA, COVID-19, Pain, American Academy, Loteprednol, Retina, Pharmaceutical industry

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Academy of Optometry (AAOPT) Annual Meeting 2021 being held in Boston, MA November 3 - 6, 2021.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Academy of Optometry (AAOPT) Annual Meeting 2021 being held in Boston, MA November 3 - 6, 2021.
  • Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors

Retrieved on: 
Monday, October 18, 2021
Infection, Incidence, History, Director, MPP, Union of Sales and Marketing Professionals, FDA, Duane syndrome, Georgia, Industrial organization, GLOBE, Private Securities Litigation Reform Act, Degenerative disease, Compensation, Trosia, Marketing, Tissue, Patient, Optic nerve, Conjunctiva, Company, Commercial, Eye, Board, Slit lamp, Visual acuity, Security (finance), KALA, Medicare Part D, Medicare, Non-executive director, Board of directors, Glaucoma, NASDAQ, Adverse drug reaction, Cornea, III, COVID-19, Ophthalmology, U.S. Securities and Exchange Commission, Steroid, Chickenpox, Eye disease, Pain, Cover My Eyes (Pain and Heaven), Mycosis, Coronavirus, Inflammation, IOP, Loteprednol, Sclera, LE, Georgia Tech, Alimera Sciences, Herpes simplex, Vaccinia, Pharmaceutical industry, Management, Vaccine

WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announcedthe appointment of C. Daniel Myers to its Board of Directors.

Key Points: 
  • WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announcedthe appointment of C. Daniel Myers to its Board of Directors.
  • We are very pleased to welcome Dan to our Board of Directors, said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals.
  • He previously served on the Board of Directors of Ocular Therapeutix, Inc. from 2009 to 2012.
  • In conjunction with Mr. Myers appointment, Kala announced that Rajeev Shah, a member of the companys Board of Directors since 2015, will be leaving the Board.

Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx

Retrieved on: 
Thursday, June 3, 2021
Biotechnology, Pharmaceutical, Optical, Health, Pharmaceuticals policy, Etabonate, Loteprednol, Pharmacy, Pharmaceutical industry in China, Chemistry, Health sciences, Health, EYSUVIS, Kala Pharmaceuticals, Inc., EYSUVIS, KALA PHARMACEUTICALS, INC.

We are pleased to announce the addition of EYSUVIS to OptumRxs commercial formularies, which represents a significant milestone towards our goal of ensuring broad market access, said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals.

Key Points: 
  • We are pleased to announce the addition of EYSUVIS to OptumRxs commercial formularies, which represents a significant milestone towards our goal of ensuring broad market access, said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals.
  • Kala commenced the promotional launch of EYSUVIS in the United States in January 2021.
  • EYSUVIS is available through both national and regional U.S. pharmaceutical distribution centers, as well as local retail pharmacies or home delivery.
  • EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% is approved for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting

Retrieved on: 
Thursday, April 29, 2021
Vision, Optometry, Health care, Health, Contact lenses, Bausch & Lomb, Bausch, Loteprednol, Prednisolone, Ophthalmic, Eye care professional, Lomb

We are proud to support these important studies and share the latest findings with eye care professionals during the ARVO meeting.

Key Points: 
  • We are proud to support these important studies and share the latest findings with eye care professionals during the ARVO meeting.
  • Bausch + Lomb announced the FDA approval of ClearVisc in April.
  • Papour et al.\n"Dose uniformity of loteprednol etabonate (submicron) ophthalmic gel 0.38% compared with prednisolone acetate ophthalmic suspension 1.0%."
  • Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna

Retrieved on: 
Tuesday, March 16, 2021
Professional services, Health, Insurance, Managed care, Pharmaceutical, Optical, Biotechnology, Corticosteroids, Loteprednol, Organochlorides, Etabonate, Ophthalmic, Chemistry, EYSUVIS, Kala Pharmaceuticals, Inc.

We are pleased to announce the addition of EYSUVIS to Cignas preferred formulary, reflecting a significant expansion of our commercial coverage and important progress toward our goal of securing broad patient access, said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals.

Key Points: 
  • We are pleased to announce the addition of EYSUVIS to Cignas preferred formulary, reflecting a significant expansion of our commercial coverage and important progress toward our goal of securing broad patient access, said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals.
  • EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% is approved for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
  • EYSUVIS utilizes Kala's proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology to enhance penetration of loteprednol etabonate (LE) into target tissue of the ocular surface.
  • Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye.